Study guide

7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios

Key Takeaways Explain This Topic AI

A frequency distribution lists each category with its count, percent (relative frequency) and often a cumulative percent; the percents must sum to 100.

The mean is the arithmetic average, the median is the middle value of ordered data, and the mode is the most frequent value; the median is preferred for skewed data such as days from diagnosis to treatment.

Relative risk (risk ratio) = risk in the exposed ÷ risk in the unexposed, calculated from cohort data; a value of 1 means no association.

Odds ratio = (a × d) ÷ (b × c) from a 2×2 table, the measure used in case-control studies; for rare diseases it approximates the relative risk.

A 95% confidence interval for a ratio that includes 1.0 means the association is not statistically significant at the 0.05 level.

Last updated: September 2026

Why registrars need basic statistics

Registrars answer data requests, prepare cancer committee and annual reports, and support quality and research studies. You do not need advanced biostatistics for the exam, but you must be able to summarize registry data correctly and interpret the risk measures that appear in the studies your data support.

Types of data

  • Type Definition Registry examples
  • Nominal (categorical) Named categories with no order Primary site, sex, race, Class of Case
  • Ordinal Ordered categories without equal spacing Stage group (I–IV), grade (1–3), performance status
  • Discrete numeric Counts Number of positive lymph nodes
  • Continuous numeric Measurements on a scale Age, tumor size in mm, days from diagnosis to treatment

The data type decides the summary. Categorical data are summarized with counts and percents , and numeric data with measures of central tendency and spread .

Frequency distributions

A frequency distribution lists each value or category with the number of cases ( frequency ), the relative frequency (percent of the total), and often the cumulative percent .

Example: stage at diagnosis for 400 analytic breast cases

  • AJCC stage group Frequency Percent Cumulative percent
  • 0 60 15.0% 15.0%
  • I 180 45.0% 60.0%
  • II 100 25.0% 85.0%
  • III 36 9.0% 94.0%
  • IV 12 3.0% 97.0%
  • Unknown 12 3.0% 100.0%
  • Total 400 100.0% —

Rules of thumb:

Always report the denominator. "45% stage I" means nothing without "n = 400."

Show unknowns. Hiding them inflates the other percentages and conceals a data quality problem.

Group continuous data into mutually exclusive, exhaustive intervals , such as age groups 0–14, 15–39, 40–64 and 65+, with no gaps or overlaps.

Choose the right chart. Use bar charts for categories, histograms for grouped continuous data, line graphs for trends over time, and pie charts only for a few parts of one whole.

Measures of central tendency

  • Measure Definition Best use
  • Mean Sum of the values ÷ number of values Roughly symmetric numeric data

Median The middle value when the data are ordered (the average of the two middle values when n is even) Skewed data or data with outliers

  • Mode The most frequent value Categorical data; finding the most common category
  • Worked example: days from diagnosis to first treatment for 9 patients

Ordered values: 12, 14, 15, 18, 21, 22, 22, 30, 160.

  • Mean = (12 + 14 + 15 + 18 + 21 + 22 + 22 + 30 + 160) ÷ 9 = 314 ÷ 9 ≈ 34.9 days
  • Median = the 5th value = 21 days
  • Mode = 22 days , the only value that appears twice

The one 160-day outlier pulls the mean up by about 14 days. The median better represents a typical patient, which is why time-to-treatment reports usually show the median.

Measures of spread

Range: maximum − minimum (160 − 12 = 148 days).

Interquartile range (IQR): the 75th percentile − the 25th percentile. It covers the middle 50% of the data and resists outliers.

Standard deviation: the typical distance of values from the mean. It is most useful with roughly bell-shaped data.

Ratios, proportions and rates

Ratio: one quantity divided by another, where the two may be unrelated (male-to-female cases, 1.2:1).

Proportion: a part divided by the whole, where the numerator is included in the denominator (the percent of cases diagnosed at stage I).

Rate: a proportion over a period of time in a population at risk (incidence per 100,000 per year; see Section 7.3).

Risk and the risk ratio (relative risk)

In a cohort study , exposed and unexposed people are followed forward in time. Arrange the results in a 2×2 table:

  • Disease No disease Total
  • Exposed a b a + b
  • Unexposed c d c + d

Risk (cumulative incidence) in the exposed = a ÷ (a + b); in the unexposed = c ÷ (c + d).

Relative risk (RR), also called the risk ratio = [a ÷ (a + b)] ÷ [c ÷ (c + d)].

Risk difference (attributable risk) = the risk in the exposed − the risk in the unexposed.

Worked example: 1,000 smokers and 2,000 non-smokers are followed for 10 years.

  • Lung cancer No lung cancer Total
  • Smokers 30 970 1,000
  • Non-smokers 6 1,994 2,000

The risk in smokers is 30/1,000 = 0.030, and in non-smokers it is 6/2,000 = 0.003.

RR = 0.030 ÷ 0.003 = 10 . Smokers had 10 times the 10-year risk.

The risk difference is 0.030 − 0.003 = 0.027, or 27 excess cases per 1,000 smokers.

The odds ratio

In a case-control study , people are selected because they have the disease (cases) or do not (controls), and past exposure is compared. The design fixes how many people have the disease, so risk cannot be calculated. The study uses the odds ratio (OR) instead:

OR = (a × d) ÷ (b × c), the cross-product of the 2×2 table.

Worked example: 200 mesothelioma cases and 400 controls are asked about asbestos exposure.

  • Cases Controls
  • Exposed 120 (a) 100 (b)
  • Unexposed 80 (c) 300 (d)

OR = (120 × 300) ÷ (100 × 80) = 36,000 ÷ 8,000 = 4.5 . The odds of past asbestos exposure were 4.5 times as high among cases as among controls. When a disease is rare , the OR approximates the RR.

Interpreting ratios

  • Value of RR or OR Interpretation
  • 1.0 No association
  • Greater than 1.0 Exposure associated with higher risk (a possible risk factor)
  • Less than 1.0 Exposure associated with lower risk (a possible protective factor)

95% confidence interval: if the interval for an RR or OR includes 1.0 (for example, 0.8–2.3), the association is not statistically significant at the 0.05 level. If it excludes 1.0 (for example, 1.4–3.9), it is.

Association is not causation. Bias, confounding (such as age or smoking) and chance must be considered before concluding that an exposure causes cancer.

Loading diagram... Choosing a summary measure